The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Outcome Measures, 2021Development of Novel Antibodies that Facilitate the Accurate Measurement of All Forms of Alpha-synuclein Present in Biological Fluids
Study Rationale: The ability to accurately detect and quantify alpha-synuclein and its pathology-relevant variants represents a major challenge in Parkinson’s disease (PD). Different studies report...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Impact of TRPML1 Stimulation on Clinical Biomarkers and Synuclein Pathology
Study Rationale: The protein TRPML1 regulates the clearance of cellular debris, including aggregated alpha-synuclein and toxic lipids—a process that is disrupted in Parkinson’s disease (PD). We have...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of Small-molecule Inhibitors that Reduce the Aggregation of Tau for the Treatment of Parkinson’s Disease
Study Rationale: The aggregation of alpha-synuclein and tau converts these proteins from a biologically functional state into toxic, fibrous deposits in the brains of people with Parkinson’s disease...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of Novel Brain-penetrant Inflammasome Inhibitors as Potential Therapeutics for Parkinson’s Disease
Study Rationale: The immune system displays an aberrant pattern of activity in the central nervous system of people with Parkinson’s disease (PD); this pattern includes activation of a danger-sensing...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of a Small-molecule Inhibitor Targeting Intracellular Alpha-synuclein Pathology
Study Rationale: Parkinson’s disease (PD) and other devastating neurodegenerative diseases, including Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA), are characterized by the...
-
Fall 2021 RFP: Outcome Measures, 2021Use of Image-enhancement Techniques to Assess Anatomical Changes in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) has several subtypes. Identification of these subtypes in individuals with PD is important for understanding disease progression, developing new therapies...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.